With lat­est Keytru­da OK, Mer­ck edges in­to Glax­o­SmithK­line’s (small) PD-1 turf

Mer­ck has col­lect­ed an­oth­er ap­proval for flag­ship PD-1 in­hibitor Keytru­da and, in do­ing so, ven­tured deep­er in­to a rel­a­tive­ly new bio­mark­er.

The ex­pand­ed OK cov­ers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER